Additional File 8 of Core Promoter Mutation Contributes to Abnormal Gene Expression in Bladder Cancer

Teng Huang,Yingbo Zhang,San Ming Wang

DOI: https://doi.org/10.6084/m9.figshare.18482110

2022-01-01

Abstract:Additional file 8: Table S7. Driver gene with core promoter mutation.

What problem does this paper attempt to address?

Core promoter mutation contributes to abnormal gene expression in bladder cancer

Teng Huang,Jiaheng Li,San Ming Wang

DOI: https://doi.org/10.1186/s12885-022-09178-z

IF: 4.638

2022-01-15

BMC Cancer

Abstract:Abstract Background Bladder cancer is one of the most mortal cancers. Bladder cancer has distinct gene expression signature, highlighting altered gene expression plays important roles in bladder cancer etiology. However, the mechanism for how the regulatory disorder causes the altered expression in bladder cancer remains elusive. Core promoter controls transcriptional initiation. We hypothesized that mutation in core promoter abnormality could cause abnormal transcriptional initiation thereby the altered gene expression in bladder cancer. Methods In this study, we performed a genome-wide characterization of core promoter mutation in 77 Spanish bladder cancer cases. Results We identified 69 recurrent somatic mutations in 61 core promoters of 62 genes and 28 recurrent germline mutations in 20 core promoters of 21 genes, including TERT , the only gene known with core promoter mutation in bladder cancer, and many oncogenes and tumor suppressors. From the RNA-seq data from bladder cancer, we observed altered expression of the core promoter-mutated genes. We further validated the effects of core promoter mutation on gene expression by using luciferase reporter gene assay. We also identified potential drugs targeting the core promoter-mutated genes. Conclusions Data from our study highlights that core promoter mutation contributes to bladder cancer development through altering gene expression.

oncology
Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Rui Cao,Lushun Yuan,Bo Ma,Gang Wang,Ye Tian

DOI: https://doi.org/10.6084/m9.figshare.12577466

2020-01-01

Abstract:Additional file 8: Table S3. Summary of ssGSEA scores for hallmark gene sets in TCGA-BLCA cohort.
Additional File 1 of Identification of a Tumor Microenvironment-Related Seven-Gene Signature for Predicting Prognosis in Bladder Cancer

Zhi Wang,Lei Tu,Minfeng Chen,Seo Yun Tong

DOI: https://doi.org/10.6084/m9.figshare.14767230

2021-01-01

Abstract:Additional file 1: Table S1. GO analysis of 4 TME-related co-expression modules (magenta, brown, purple and yellow).
Additional File 5 of Dysregulation and Prometastatic Function of Glycosyltransferase C1GALT1 Modulated by Chp1bp3/ Mir-1-3p Axis in Bladder Cancer

Zengqi Tan,Yazhuo Jiang,Liang,Jinpeng Wu,Lin Chen,Xiaoman Zhou,Zhihui Song,Zhenyu Ye,Ziyan Zhao,Feng Hong,Zewen Dong,Shuai Lin,Zhangjian Zhou,Yili Wang,Xiang Li,Guosheng Feng

DOI: https://doi.org/10.6084/m9.figshare.20356380

2022-01-01

Abstract:Additional file 5: Table S5. Proteins modified with T antigen identified in control and C1GALT1 silenced YTS-1 cells.
Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Chenyu Mao,Nong Xu

DOI: https://doi.org/10.2174/0929867331666230824093312

IF: 4.74

2024-01-01

Current Medicinal Chemistry

Abstract:BACKGROUND:The highly heterogeneous, complex pathological histology, and clinical phenotype in bladder cancer (BC) plague the prognostic management of BC to the present day.METHODS:This study was conducted using single-cell sequencing data from the gene expression omnibus (GEO) database (GSE135337). A descending, annotated analysis was performed to identify the cell types contributing to BC aggressiveness. BC cell sequencing data from The Cancer Genome Atlas (TCGA) database were then combined with univariate, least absolute shrinkage and selection operator (LASSO), multivariate COX regression analysis to identify biomarkers of BC prognosis to construct a BC. We identified biomarkers of BC prognosis to construct a prognostic risk guidance system for BC. The feedback of patients in different risk strata to immunotherapy was analyzed. Finally, the regulation of prognostic genes on cancer cell activity was verified in vitro by Western blot and cell counting kit-8 (CCK8) assays.RESULTS:Macrophages specifically expressing CD68 in BC were the cell type with the highest AUCell score, and CD68 was the biomarker of Tumor-associated macrophages (TAMs). CD68 macrophages were potentially the critical cell type in the aggressive BC subtype. Through univariate, LASSO, multivariate COX-based regression analysis. CTSS, GMFG, ANXA5, GSN, SLC2A3, and FTL were authenticated as prognostic biomarkers (p < 0.05) and composed the Risk Score. Patients in the low-risk group showed an excellent survival advantage (p < 0.01) and immunotherapy feedback. Additionally, inhibition of GSN expression decreased EMT activity to inhibit bladder cancer cell viability.CONCLUSION:In conclusion, this study provided feedback on the immune cell types associated with aggressiveness in BC. Importantly, a prognostic management system for BC was created based on the genes involved, providing more insight into the aggressive pathological phenotype as well as the prognosis of BC.
Additional File 1 of Wnt Pathway-Related Three-Mrna Clinical Outcome Signature in Bladder Urothelial Carcinoma: Computational Biology and Experimental Analyses

Shengrong Sun,Yutao Wang,Jianfeng Wang,Jianbin Bi

DOI: https://doi.org/10.6084/m9.figshare.16689587

2021-01-01

Abstract:Additional file 1. Table S1. The list of WNT pathway genes name in KEGG.
Abstract A52: Gene Alterations Associated with Clinical Characteristics of Bladder Cancer

Mike Nickerson,Kate M. Im,Guangwu Guo,Yaoting Gui,Sevilay Turan,James C. Costello,Quan Zhou,Zhiming Cai,Song Wu,M. Scott Lucia,Lee E. Moore,Michael Dean,Dan Theodorescu

DOI: https://doi.org/10.1158/1538-7445.chromepi15-a52

IF: 11.2

2016-01-01

Cancer Research

Abstract:Abstract Next-generation sequencing (NGS) of urologic tumor genomes has identified frequently altered cancer genes. We recently examined the exomes of bladder tumors (BCa) from 54 U.S. patients and 99 Chinese patients to identify novel, altered cancer genes associated with clinical characteristics of disease. Exome capture of DNA from tumor and normal urothelial tissue using probes for ~180,000 protein-coding exons and microRNA loci; DNA fragment libraries were sequenced on a HiSeq 2000 platform (Illumina); and base calls on paired-end, 100 bp reads were generated using the Genome Analyzer Pipeline, v. 1.3 and standard parameters. Gene expression was analyzed using quantitative PCR, telomere length by a standard assay, and KDM6A function using cell-based assays in T24T BCa cells. Copy number variation (CNV), aneuploidy, and CpG methylation were analyzed as recently described. Telomerase (TERT) was the most frequently altered by somatic sequence changes in 37/54 (69%) of U.S. patient tumors. The TERT promoter was altered by frequent germline nucleotide changes in 30/54 (56%) tumors. Most of the TERT germline variants were novel (19/20) and three variants were confirmed in distinct tumors as either somatic or germline, including the most frequent variant, c. –245 T>C (rs2853669). The somatic TERT promoter alterations did not correlate with other somatic BCa gene alterations, but were associated with increased TERT expression and with significantly shorter telomeres in tumors as compared to matched normal tissue. The stromal antigen 2 (STAG2) gene was the most frequently altered novel BCa gene in Chinese patients, by somatic, deleterious sequence changes in 11% of tumors; CNV deletions (5%); and promoter CpG hypermethylation leading to presumed expression silencing (7/30, 23%). STAG2 encodes a component of the cohesion complex involved in sister chromatid cohesion and segregation. STAG2 mutations were associated with an increased number of chromosomal arm copy number changes corresponding to higher tumor cell aneuploidy, and mutations were associated with a significantly reduced patient survival by Kaplan-Meier survival analysis. In total, 32/99 (32%) of tumors displayed SCCS pathway gene alterations. The most frequently altered epigenetic gene was the histone lysine-specific demethylase 6A (KDM6A/UTX) in 24% of U.S. and 30% of Chinese patient tumors. Experimentally, we show KDM6A loss in human BCa T24T cells enhanced in vitro proliferation and cell migration, and in vivo tumor growth in mice. Re-expression reversed these effects, confirming KDM6A loss drives the BCa phenotype. Somatic KDM6A alterations were associated with somatic BRCA1-associated protein-1 (BAP1) alterations observed in 15% of U.S. tumors. Somatic, deleterious sequence changes occurred preferentially in U.S. Caucasian as compared to Chinese BCa patient tumors; are associated with papillary histologic features in a subset of tumors; and contribute to a significant number of tumors (10/14, 71%) that displayed alteration of genes encoding BRCA DNA repair pathway proteins. Genes encoding BRCA pathway proteins, including BAP1, BRCA1, BRCA2, PALB2, and ATM were altered by a combination of somatic and rare germline variants. We identified altered genes associated with clinical characteristics of BCa, including ‘immortalization' (TERT), aneuploidy (STAG2), proliferation (KDM6A), and papillary features in tumors (BAP1). STAG2 alterations are associated with a reduced patient survival, indicating a lethal subtype of disease; and altered X chromosome genes (STAG2 and KDM6A) are single copy in males and likely contribute to the cancer gender bias. Finally, we identified BRCA pathway alterations in BCa that are similar to those in breast, ovarian, prostate and kidney tumors, that have a common DNA repair deficiency that can be exploited by therapy targeting poly (ADP ribose) polymerase. Citation Format: Mike Nickerson, Kate M. Im, Guangwu Guo, Yaoting Gui, Sevilay Turan, James C. Costello, Quan Zhou, Zhiming Cai, Song Wu, M. Scott Lucia, Lee E. Moore, Michael Dean, Dan Theodorescu. Gene alterations associated with clinical characteristics of bladder cancer. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr A52.
Additional File 11 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Rui Cao,Lushun Yuan,Bo Ma,Gang Wang,Ye Tian

DOI: https://doi.org/10.6084/m9.figshare.12577427

2020-01-01

Abstract:Additional file 11: Table S4. The detailed information of immunotherapy response based on TIDE algorithm in TCGA-BLCA cohort.
Identification of Gene Expression Profiles and Immune Cell Infiltration Signatures Between Low and High Tumor Mutation Burden Groups in Bladder Cancer.

Zonglong Wu,Muru Wang,Qinggang Liu,Yaxiao Liu,Kejia Zhu,Lipeng Chen,Hongda Guo,Yan Li,Benkang Shi

DOI: https://doi.org/10.7150/ijms.39056

2020-01-01

International Journal of Medical Sciences

Abstract:Bladder cancer is one of the most commonly diagnosed tumors and is results from the accumulation of somatic mutations in the DNA. Tumor mutation burden (TMB) has been associated with cancer immunotherapeutic response. In this study, we attempted to explore the correlation between TMB and cancer prognosis. Identify the different expressed genes and immune cell infiltration signatures between low and high TMB group. Mutation data, gene expression profiles and clinical data were downloaded from The Cancer Genome Atlas (TCGA) database. Patients were divided into high and low TMB groups, allowing differentially expressed genes (DEGs) to be identified. Functional enrichment and protein-protein interaction (PPI) network analysis were used to identify the functions of the DEGs. And immune cell infiltration signatures were evaluated by CIBERSORT algorithm. These results shown that high TMB was significantly associated with prognosis. We obtained a list of TMB related genes which may influence the infiltrations of immune cells. We also found a higher proportion of CD8 T cells, CD4 T cells and NK cells in the high TMB group. Our data suggest that higher TMB tends to promote the infiltrations of T cells and NK cells and patients with higher TMB may achieve a more favorable prognosis in bladder cancer.
Additional File 8 of the Immune Subtypes and Landscape of Sarcomas

Wei‐Hung Weng,Yuling Lin,Zhang Li,Cong Tan,Jiaoyan Lv,I Weng Lao,Wenhuo Hu,Zhenzhong Deng,Zebing Liu,Jian Wang,Ming Xu

DOI: https://doi.org/10.6084/m9.figshare.21202086

2022-01-01

Abstract:Additional file8. Table S5: List of six prognostic genes in the blue module.
Additional File 5 of Highly Diversified Core Promoters in the Human Genome and Their Effects on Gene Expression and Disease Predisposition

Hemant Gupta,Khyati Chandratre,Siddharth Sinha,Teng Huang,Xiaobing Wu,Jian Cui,Michael Q. Zhang,San Ming Wang

DOI: https://doi.org/10.6084/m9.figshare.13311175

2020-01-01

Abstract:S5. Simple repeats identified in core promoter region
Whole-genome and Whole-Exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation

Guangwu Guo,Xiaojuan Sun,Chao Chen,Song Wu,Peide Huang,Zesong Li,Michael Dean,Yi Huang,Wenlong Jia,Quan Zhou,Aifa Tang,Zuoquan Yang,Xianxin Li,Pengfei Song,Xiaokun Zhao,Rui Ye,Shiqiang Zhang,Lin Zhao,Mingfu Qi,Shengqing Wan,Liangfu Xie,Fan,Michael L. Nickerson,Xiangjun Zou,Xueda Hu,Xing Li,Zhaojie Lv,Hongbin Mei,Shengjie Gao,Chaozhao Liang,Zhibo Gao,Jingxiao Lu,Yuan Yu,Chunxiao Liu,Liang‐In Lin,Xiaodong Fang,Ziyu Jiang,Jie Yang,Cailing Li,Xin Zhao,Jing Chen,Fang Zhang,Y,Zheguang Lin,Fangjian Zhou,Hao Chen,Hsiao Chang Chan,Shirley Tsang,Dan Theodorescu,Yingrui Li,Xiuqing Zhang,Jian Wang,Huanming Yang,Yaoting Gui,Jun Wang,Zhiming Cai

DOI: https://doi.org/10.1038/ng.2798

IF: 30.8

2013-01-01

Nature Genetics

Abstract:Bladder cancer is one of the most common cancers worldwide, with transitional cell carcinoma (TCC) being the predominant form. Here we report a genomic analysis of TCC by both whole-genome and whole-exome sequencing of 99 individuals with TCC. Beyond confirming recurrent mutations in genes previously identified as being mutated in TCC, we identified additional altered genes and pathways that were implicated in TCC. Notably, we discovered frequent alterations in STAG2 and ESPL1, two genes involved in the sister chromatid cohesion and segregation (SCCS) process. Furthermore, we also detected a recurrent fusion involving FGFR3 and TACC3, another component of SCCS, by transcriptome sequencing of 42 DNA-sequenced tumors. Overall, 32 of the 99 tumors (32%) harbored genetic alterations in the SCCS process. Our analysis provides evidence that genetic alterations affecting the SCCS process may be involved in bladder tumorigenesis and identifies a new therapeutic possibility for bladder cancer.
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis

Tadeusz Majewski,Hui Yao,Jolanta Bondaruk,Woonbok Chung,Sangkyou Lee,June Goo Lee,Shizhen Zhang,David Cogdell,Guoliang Yang,Woonyoung Choi,Colin Dinney,H. Barton Grossman,Christopher Logothetis,Steven E. Scherer,Charles C. Guo,Li Zhang,Peng Wei,John N. Weinstein,Jean-Pierre Issa,Keith Baggerly,David J. McConkey,Bogdan Czerniak

DOI: https://doi.org/10.1016/j.celrep.2019.01.095

2018-01-01

Abstract:We used whole-organ mapping to study the locoregional molecular changes in a human bladder containing multifocal cancer. Widespread DNA methylation changes were identified in the entire mucosa, representing the initial field effect. The field effect was associated with subclonal low-allele frequency mutations and a small number of DNA copy alterations. A founder mutation in the RNA splicing gene, ACIN1, was identified in normal mucosa and expanded clonally with an additional 21 mutations in progression to carcinoma. The patterns of mutations and copy number changes in carcinoma in situ and foci of carcinoma were almost identical, confirming their clonal origins. The pathways affected by the DNA copy alterations and mutations, including the Kras pathway, were preceded by the field changes in DNA methylation, suggesting that they reinforced mechanisms that had already been initiated by methylation. The results demonstrate that DNA methylation can serve as the initiator of bladder carcinogenesis.
Abstract 3161: Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies

Jim Jinn-Chyuan Sheu,Chung Chang,Bo-Chen Lin,Tritium Hwang

DOI: https://doi.org/10.1158/1538-7445.am2023-3161

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract We have previously developed a unique HD-MAC (high-dimensional analysis of molecular alterations in cancer) platform that enables us to define independent tumor biomarkers from a group of clinically-significant genes. Using this platform, 26 genes were identified as independent prognosis biomarkers whose overexpression determine shorter overall survivals in patients with bladder cancer. Through clinical association study (including tumor stage, lymph node invasion, angiogenesis, and metastasis), a gene signature containing 6 biomarkers was established which can be validated by two independent cohorts. Gene knock down effects on cancer cell survival further revealed PPT2 and PRPF19 as potential targets for target-based therapy. Correlation study between genetic dependencies and drug sensitivities across cell lines suggested several potent lead compounds which are likely to function through similar mechanisms of gene effect actions. Our study therefore provides newly defined prognostic biomarkers as well as the associated therapeutic strategies for possible clinical applications in patients with bladder cancer. Citation Format: Jim Jinn-Chyuan Sheu, Chung Chang, Bo-Chen Lin, Tritium Hwang. Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3161.

oncology
Additional File 5 of Bladder Cancer-Derived Exosomal KRT6B Promotes Invasion and Metastasis by Inducing EMT and Regulating the Immune Microenvironment

Qiang Song,Hao Yu,Yidong Cheng,Jie Han,Kai Li,Juntao Zhuang,Qiang Lu,Xiao Yang,Haiwei Yang

DOI: https://doi.org/10.6084/m9.figshare.20252771

2022-01-01

Abstract:Additional file 5: Table S5. Mean expression level of KRT6B.
Coexistence of YWHAZ Amplification Predicts Better Prognosis in Muscle-Invasive Bladder Cancer with CDKN2A or TP53 Loss

Shenghua Liu,Yishuo Wu,Tian Yang,Chenchen Feng,Haowen Jiang

DOI: https://doi.org/10.18632/oncotarget.9158

2016-01-01

Oncotarget

Abstract:The amplification of YWHAZ was commonly seen in bladder cancer. We explore the biological significance of YWHAZ amplification on bladder cancer, and the correlation with important other molecular events. The Cancer Genome Atlas (TCGA) database was exploited to study the impact of YWHAZ amplification on either CDKN2A or TP53 mutations. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was also exploited to clustering of enriched genes in the cBioPortal Enrichment tests. There were 127 cases with available mutation and CNV data in the corresponding TCGA bladder cancer dataset, 20% of them had YWHAZ alteration. Patients with both YWHAZ amplification and CDKN2A loss demonstrated significantly better overall survival (OS) compared with CDKN2A loss alone. Patients with both YWHAZ amplification and TP53 mutation demonstrated significantly better overall survival (OS) and disease-free survival (DFS) compared with TP53 mutation alone. The amplification of YWHAZ, along with alteration of CDKN2A or TP53, predict better survival in bladder cancers that only had CDKN2A or TP53 alteration. The protective role of YWHAZ in bladder cancer deserve insightful further studies.
Aberrant FBXW7-mediated Ubiquitination and Degradation of ZMYND8 Enhances Tumor Progression and Stemness in Bladder Cancer.

Feng Qiu,Yichen Jin,Jinxian Pu,Yuhua Huang,Jianquan Hou,Xiaojun Zhao,Yong Lu

DOI: https://doi.org/10.1016/j.yexcr.2021.112807

IF: 4.145

2021-01-01

Experimental Cell Research

Abstract:ZMYND8, an epigenetic regulator, was identified as a common oncogene across various tumors. However, little was reported about the association between ZMYND8 and bladder cancer. Besides, aberrant mechanisms that contribute to abnormal ZMYND8 expressions still remain unclear. In the current study, we first found that ZMYND8 protein levels were significantly elevated in Bca samples versus normal tissues, but not the mRNA levels. We then utilized the Cell Counting Kit-8 (CCK-8) assay, clone formation assay and transwell analysis to confirm that ZMYND8 could remarkably promote the tumor progression in vitro, including growth capacity and migration. Bioinformatic predictive analysis revealed that E3 ubiquitin ligase FBXW7 interacts directly with ZMYND8 and degrades ZMYND8 in a polyubiquitination manner. Low FBXW7 was a hazard factor for promoting and depending on accumulated ZMYND8 proteins to promote Bca progression. Gene set enrichment analysis (GSEA) further indicated that ZMYND8 was notably associated with stemness process, which was well functionally validated. Lastly, ZMYND8 deficiency was observed to inhibit tumor growth of Bca in vivo, revealing a promising translational significance in Bca treatment. In conclusion, our study for the first time provided evidence for a novel mechanism of FBXW7/ZMYND8 axis in Bca, providing therapeutic vulnerability for individualized cancer treatment.
Supplementary Figure S2 from Concurrent Alterations in <i>tert</i>, <i>kdm6a</i>, and the BRCA Pathway in Bladder Cancer

Michael L. Nickerson,Garrett M. Dancik,Kate M. Im,Michael G. Edwards,Sevilay Turan,Joseph Brown,Christina Ruiz-Rodriguez,Charles Owens,James C. Costello,Guangwu Guo,Shirley X. Tsang,Yingrui Li,Quan Zhou,Zhiming Cai,Lee E. Moore,M. Scott Lucia,Michael Dean,Dan Theodorescu

DOI: https://doi.org/10.1158/1078-0432.22455171.v1

2023-01-01

Abstract:Bladder cancer network containing debiquitinating enzymes (DUBs), chromosome remodeling genes and genes associated with VEGF signaling.
Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer

Jingchao Liu,Jianlong Wang,Meng Wu,Wei Zhang,Lingfeng Meng,Jiawen Wang,Zhengtong Lv,Haoran Xia,Yaoguang Zhang,Jianye Wang

DOI: https://doi.org/10.3389/fmed.2021.757432

IF: 3.9

2021-12-23

Frontiers in Medicine

Abstract:Purpose: To comprehensively analyze N6-methyladenosine modification patterns in bladder tumors and to further systematically explore the inherent relationships between these modification patterns and multiomic tumor characteristics. Materials and Methods: A total of 901 bladder tumor samples, including 405 samples from TCGA database, 188 samples from GSE13507 and 308 samples from GSE32894, were included in this systematic analysis. The N6-methyladenosine modification patterns were identified utilizing unsupervised clustering analysis. To quantify N6-methyladenosine modification patterns, the m6Ascore of individual sample was developed using principal component analysis algorithms. Relationships among immune infiltration, tumor mutation burden, various clinical characteristics, molecular subtypes, and the m6Ascore were systematically analyzed. The guiding value of m6Ascore in immunotherapy was further validated in an external trial cohort. Genomics of Drug Sensitivity in Cancer expression references were also utilized to perform drug sensitivity analysis for patients with distinct m6A modification patterns. Results: We determined three different N6-methyladenosine modification patterns for 901 bladder tumors. The quantitative m6Ascore of individual sample derived from N6-methyladenosine modification patterns could play a significant role in predicting overall survival, immune cell infiltration, and classic oncogene mutations. A low m6Ascore combined with high tumor mutation burden indicated better survival outcomes ( p < 0.001). A higher m6Ascore also indicated a higher grade, higher T and N stage, elder ages, higher death rate, and higher PD1/PDL1/CTLA4 expressions ( p < 0.01). The Basal type tended to exhibit significantly higher m6Ascores than the Luminal and Neuronal subtypes. External immunotherapy cohorts demonstrated that no difference in therapeutic effects was noted between the high and low m6Ascore groups when anti-PD1 immunotherapy was exclusively administered. When anti-PD1 and anti-CTLA4 immunotherapy were simultaneously administered, the high m6Ascore group had a significantly better prognosis than the low m6Ascore group ( p < 0.001). High m6A groups were potentially sensitive to various medical treatments including Bleomycin, Bortezomib, Cisplatin, Cyclopamine, Dasatinib, Docetaxe, Rapamycin, and Vinblastine in this study. Conclusions: This study systematically revealed the important roles of m6A methylation modification patterns in bladder tumors. Detailed quantification of m6A modification patterns could improve our understanding of the bladder tumor microenvironments and could provide guidance for future immunotherapy strategies.

medicine, general & internal
Supplementary Table 1 from TGF-β–Induced Upregulation of Malat1 Promotes Bladder Cancer Metastasis by Associating with Suz12

Yu Fan,Bing Shen,Mingyue Tan,Xinyu Mu,Yan Qin,Fang Zhang,Yong Liu

DOI: https://doi.org/10.1158/1078-0432.22450890

2023-01-01

Abstract:PDF file - 140K, Associations of malat1 expression with clinical pathologic features in patients with bladder cancer.

Additional File 8 of Core Promoter Mutation Contributes to Abnormal Gene Expression in Bladder Cancer

Core promoter mutation contributes to abnormal gene expression in bladder cancer

Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Additional File 1 of Identification of a Tumor Microenvironment-Related Seven-Gene Signature for Predicting Prognosis in Bladder Cancer

Additional File 5 of Dysregulation and Prometastatic Function of Glycosyltransferase C1GALT1 Modulated by Chp1bp3/ Mir-1-3p Axis in Bladder Cancer

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Additional File 1 of Wnt Pathway-Related Three-Mrna Clinical Outcome Signature in Bladder Urothelial Carcinoma: Computational Biology and Experimental Analyses

Abstract A52: Gene Alterations Associated with Clinical Characteristics of Bladder Cancer

Additional File 11 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Identification of Gene Expression Profiles and Immune Cell Infiltration Signatures Between Low and High Tumor Mutation Burden Groups in Bladder Cancer.

Additional File 8 of the Immune Subtypes and Landscape of Sarcomas

Additional File 5 of Highly Diversified Core Promoters in the Human Genome and Their Effects on Gene Expression and Disease Predisposition

Whole-genome and Whole-Exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation

Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis

Abstract 3161: Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies

Additional File 5 of Bladder Cancer-Derived Exosomal KRT6B Promotes Invasion and Metastasis by Inducing EMT and Regulating the Immune Microenvironment

Coexistence of YWHAZ Amplification Predicts Better Prognosis in Muscle-Invasive Bladder Cancer with CDKN2A or TP53 Loss

Aberrant FBXW7-mediated Ubiquitination and Degradation of ZMYND8 Enhances Tumor Progression and Stemness in Bladder Cancer.

Supplementary Figure S2 from Concurrent Alterations in &lt;i&gt;tert&lt;/i&gt;, &lt;i&gt;kdm6a&lt;/i&gt;, and the BRCA Pathway in Bladder Cancer

Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer

Supplementary Table 1 from TGF-β–Induced Upregulation of Malat1 Promotes Bladder Cancer Metastasis by Associating with Suz12

Supplementary Figure S2 from Concurrent Alterations in <i>tert</i>, <i>kdm6a</i>, and the BRCA Pathway in Bladder Cancer